Rainsford K D
Int J Tissue React. 1985;7(2):123-6.
Catabolin/Interleukin 1 (CAT-IL-1) comprises a family of acidic proteins produced by stimulated monocytes and inflamed synovium which cause the release of proteoglycans and collagen from living cartilage in vitro. The possible relevance of these proteins as mediators of joint destruction in animal models of joint damage and in arthritic disease in man has yet to be determined. To establish if conventional or novel anti-inflammatory (AI) agents could modify the actions of CAT-IL-1 and thus be useful for understanding the mode of action of these components, the effects were determined of a range of AI compounds on the release by CAT-IL-1 of proteoglycans (PG's) from bovine nasal cartilage. In vitro, conventional non-steroidal anti-inflammatory (NSAI) compounds were, with the exception of 10-100 microM hydroxychloroquine, weak (e.g. diclofenac, indomethacin, fenclofenac, effective at concentrations of 100-500 microM), or with some drugs actually ineffective, as inhibitors of CAT-IL-1-mediated PG release. Antioxidants were ineffective as inhibitors of this PG release. Drugs which modify gene transcription were potent inhibitors of CAT-IL-1-induced PG release, emphasizing the importance of gene expression in the actions of these mediators. The importance of prostaglandin metabolism on CAT-IL-1 actions and the in vivo effects of AI are discussed.
分解代谢素/白细胞介素1(CAT-IL-1)由受刺激的单核细胞和炎症滑膜产生的一类酸性蛋白质组成,这些蛋白质在体外可导致蛋白聚糖和胶原蛋白从活软骨中释放出来。这些蛋白质作为关节损伤动物模型和人类关节炎疾病中关节破坏介质的潜在相关性尚未确定。为了确定传统或新型抗炎(AI)药物是否能改变CAT-IL-1的作用,从而有助于理解这些成分的作用模式,研究了一系列AI化合物对CAT-IL-1从牛鼻软骨释放蛋白聚糖(PG)的影响。在体外,除10 - 100微摩尔羟氯喹外,传统非甾体抗炎(NSAI)化合物作为CAT-IL-1介导的PG释放抑制剂作用较弱(如双氯芬酸、吲哚美辛、芬氯酸,在100 - 500微摩尔浓度下有效),或某些药物实际上无效。抗氧化剂作为这种PG释放的抑制剂无效。改变基因转录的药物是CAT-IL-1诱导的PG释放的有效抑制剂,强调了基因表达在这些介质作用中的重要性。讨论了前列腺素代谢对CAT-IL-1作用的重要性以及AI的体内效应。